Eli Lilly (LLY +0.70%) is the most valuable healthcare company, with Johnson & Johnson (JNJ +0.43%) and AbbVie (ABBV -0.88%) rounding out the top three. Pharmaceutical companies dominate this market sector, comprising half of the largest healthcare companies by market cap. Let's take a look at the companies that could be a financial cure-all for investors and their portfolios.
Largest companies by market cap in the healthcare sector
(Editor's note: Rankings are as of March 5, 2026.)
| Name and ticker | Market cap | Current price | Industry |
|---|---|---|---|
| Eli Lilly (NYSE:LLY) | $934.2 billion | $990.18 | Pharmaceuticals |
| Johnson & Johnson (NYSE:JNJ) | $579.3 billion | $240.66 | Pharmaceuticals |
| AbbVie (NYSE:ABBV) | $406.9 billion | $230.31 | Biotechnology |
| Novartis (NYSE:NVS) | $305.5 billion | $160.27 | Pharmaceuticals |
| AstraZeneca Plc (NASDAQ:AZN) | N/A | N/A | Pharmaceuticals |
| Merck (NYSE:MRK) | $286.3 billion | $115.87 | Pharmaceuticals |
| UnitedHealth Group (NYSE:UNH) | $260.0 billion | $286.86 | Healthcare Providers and Services |
| Amgen (NASDAQ:AMGN) | $199.2 billion | $369.53 | Biotechnology |
| Thermo Fisher Scientific (NYSE:TMO) | $186.5 billion | $501.97 | Life Sciences Tools and Services |
| Abbott Laboratories (NYSE:ABT) | $190.4 billion | $109.73 | Healthcare Equipment and Supplies |
1. Eli Lilly
- Market cap: $880.04 billion (as of March 5)
- Revenue (TTM): $65.2 billion
- Gross profit (TTM): $54.1 billion
- Five-year annualized return: 38.00%
- Year founded: 1876
NYSE: LLY
Key Data Points
Pharmaceutical giant Eli Lilly is the world's most valuable drug company. A chemist and veteran of the Union Army founded the company in 1876, and it later became the first to mass-produce insulin and the polio vaccine.
Some of its top products are diabetes medications, weight loss drugs, obesity treatments, and antidepressants such as Prozac. In 2024, Eli Lilly partnered with Amazon (AMZN -2.62%) to offer home delivery of select medications. In November 2025, it agreed to a deal with the Trump administration to offer reduced pricing on some of its drugs, including weight loss blockbuster Zepbound.
2. Johnson & Johnson
- Market cap: $577.48 billion (as of March 5)
- Revenue (TTM): $94.2 billion
- Gross profit (TTM): $63.9 billion
- Five-year annualized return: 9.89%
- Year founded: 1886
NYSE: JNJ
Key Data Points
Johnson & Johnson is one of the leading pharmaceutical and medical device companies. Its two primary business segments are Innovative Medicine, which develops and markets prescription drugs, and MedTech, which manufactures medical devices, including Acuvue contact lenses.
Until 2023, Johnson & Johnson also had a robust consumer healthcare division that produced Tylenol, Band-Aid, and many other household names. It spun off that division into a new business, Kenvue (KVUE +0.77%), which agreed in late 2025 to be purchased by consumer goods giant Kimberly-Clark (KMB +0.92%) in a $48.7 billion deal.
3. AbbVie
- Market cap: $410.83 billion (as of March 5)
- Revenue (TTM): $61.2 billion
- Gross profit (TTM): $43.0 billion
- Five-year annualized return: 17.46%
- Year founded: 2012
NYSE: ABBV
Key Data Points
AbbVie is a biotechnology company that develops treatments for serious diseases. It has produced therapies for illnesses, including autoimmune diseases, plaque psoriasis, blood cancers, and advanced Parkinson's disease. It also acquired Capstan Therapeutics, a cell and gene therapy company, for $2.1 billion in mid-2025.
AbbVie is a relatively new company that started as a spinoff of Abbott Laboratories (ABT -1.18%). It's now one of the better dividend stocks in the healthcare sector. It has regularly raised its dividend payout, resulting in a high dividend yield.
4. Novartis
- Market cap: $311.24 billion (as of March 5)
- Revenue (TTM): $56.7 billion
- Gross profit (TTM): $43.0 billion
- Five-year annualized return: 15.88%
- Year founded: 1886 (Sandoz), 1970 (Ciba-Geigy), 1996 (merger of Ciba-Geigy and Sandoz)
NYSE: NVS
Key Data Points
NASDAQ: AZN
Key Data Points
AstraZeneca (NASDAQ:AZN) is a multinational biotech company formed through the 1999 merger of Astra, a Swiss company, and Zeneca, a British company. Its headquarters are in Cambridge, U.K.
This company manufactures prescription medications for many major diseases, including cardiovascular disease, metabolic disorders, renal disease, and rare diseases. It has 11 research and development (R&D) centers, 28 manufacturing sites, and a market presence in more than 130 countries.
6. Merck
- Market cap: $286.97 billion (as of March 5)
- Revenue (TTM): $65.0 billion
- Gross profit (TTM): $48.6 billion
- Five-year annualized return: 11.82%
- Year founded: 1891
NYSE: MRK
Key Data Points
Merck (MRK -0.17%) is a pharmaceutical company known for its impressive oncology portfolio. That includes its leading drug, Keytruda, which is one of the best-selling drugs worldwide. Merck also makes diabetes medications, an HPV vaccine, and a chickenpox vaccine.
This company has made several major acquisitions recently. In 2024 alone, it acquired Harpoon Therapeutics, Abceutics, EyeBio, and Modifi Biosciences. In 2025, it acquired SpringWorks Therapeutics for $3.4 billion. Merck is also going through a leadership transition; CEO Belen Garijo will step down at the end of April 2026. Her successor will be Kai Beckmann, head of the company's electronics business.
7. UnitedHealth Group
- Market cap: $261.58 billion (as of March 5)
- Revenue (TTM): $447.6 billion
- Gross profit (TTM): $82.9 billion
- Five-year annualized return: -2.64%
- Year founded: 1977
NYSE: UNH
Key Data Points
UnitedHealth Group (UNH -0.66%) provides health insurance and healthcare services. It sells health insurance products through its UnitedHealthcare division and offers healthcare services through its Optum division.
Although UnitedHealth Group is one of the largest healthcare companies, it has faced a number of high-profile issues. A subsidiary, Change Healthcare, was responsible for the largest reported healthcare data breach in history in 2024. CEO Andrew Witty abruptly resigned in May 2025 for personal reasons, and the company replaced its CFO in July.
8. Amgen
- Market cap: $198.16 billion (as of March 5)
- Revenue (TTM): $36.7 billion
- Gross profit (TTM): $24.7 billion
- Five-year annualized return: 11.32%
- Year founded: 1980
NASDAQ: AMGN
Key Data Points
Amgen (AMGN +0.51%) is a biotechnology and pharmaceutical company with a presence in about 100 countries. It focuses on areas of high unmet medical need and conditions for which there are limited treatment options. The company develops treatments in the following therapeutic areas: general medicine, rare disease, inflammation, and oncology.
Some of Amgen's best-selling products include Enbrel, an anti-inflammatory medicine; Prolia, an osteoporosis treatment in women after menopause; and Otezla, a medicine for adults with moderate to severe plaque psoriasis.
9. Thermo Fisher Scientific
- Market cap: $194.93 billion (as of March 5)
- Revenue (TTM): $44.6 billion
- Gross profit (TTM): $18.5 billion
- Five-year annualized return: 3.04%
- Year founded: 1902 (Fisher Scientific), 1956 (Thermo Electron), 2006 (merged into Thermo Fisher Scientific)
NYSE: TMO
Key Data Points
Thermo Fisher Scientific (TMO -3.25%) is a life science and research company. It has a large, diverse portfolio of products that includes analytical equipment, diagnostic kits and instruments, and life science products used in medical research and diagnostics.
This Massachusetts-based company has operations around the world. It also employs approximately 125,000 people. In September 2025, Thermo Fisher expanded its Life Sciences Solutions segment by acquiring the purification and filtration business of Solventum (SOLV -2.16%) for $4 billion. In October, it agreed to acquire life sciences company Clario for $9 billion.
10. Abbott Laboratories
- Market cap: $192.95 billion (as of March 5)
- Revenue (TTM): $44.3 billion
- Gross profit (TTM): $25.0 billion
- Five-year annualized return: -0.51%
- Year founded: 1888
NYSE: ABT
Key Data Points
Abbott Laboratories manufactures healthcare products and medical equipment. It has four main business segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.
In November 2025, this healthcare company announced an agreement to buy Exact Sciences (EXAS +0.18%), a company that specializes in the detection of early-stage cancers, for approximately $21 billion.
Like its spinoff AbbVie, Abbott Laboratories is popular among dividend investors. It has raised its dividend for more than 50 consecutive years, putting it on the list of Dividend Kings.
Healthcare sector takeaways for investors
Investing in healthcare stocks can be challenging, as the sector has some unique risks. The development of new products often requires a lengthy regulatory process, particularly for pharmaceutical companies. And if a company's product may have caused harm to a consumer, there's the possibility of a lawsuit.
Trump's tariffs could increase the cost of medical devices and pharmaceutical products. Eli Lilly, Johnson & Johnson, and AstraZeneca are all investing heavily to expand their U.S. manufacturing to reduce the potential impact of tariffs.
Even with those risks, there are also plenty of reasons why healthcare is an attractive sector for investors. Some of the top healthcare companies pay high dividends, which is great for investors looking to build passive income. Healthcare stocks also tend to be resistant to market downturns. After all, no matter how the economy is doing, people always need healthcare.
Related investing topics
FAQ
Largest healthcare companies FAQ
About the Author
Lyle Daly has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, Amazon, AstraZeneca Plc, Intuitive Surgical, Kenvue, Merck, and Thermo Fisher Scientific. The Motley Fool recommends Johnson & Johnson, Solventum, and UnitedHealth Group. The Motley Fool has a disclosure policy.
